Abbott Reports Trial Results for Esprit BTK in Chronic Limb-Threatening Ischemia (CLTI)
Shots:
- The (LIFE-BTK) trial evaluates the safety & efficacy of the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK) vs Balloon Angioplasty (SoC) in patients (n=261) with CLTI. The trial results were presented at the TCT Conference 2023 & was published in the New England Journal of Medicine
- As per the results, Esprit BTK depicted higher independence from the primary efficacious clinical events vs SoC (74.5 vs 43.7%) along with an improved reduction in vessel re-narrowing (25.8%) & sustained openness of the vessels (14.2%)
- Esprit BTK is a drug-eluting resorbable scaffold made of components similar to dissolving sutures, a temporary implant that functions & provides support until the blockage is cleared
Ref: Abbott | Image: Abbott
Related News:- Abbott to Acquire Bigfoot Biomedical to Develop Personalized, Connected Solutions for Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
